Richard C Koya

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
    Adrian Bot
    Kite Pharma Inc, Los Angeles, CA, USA
    J Transl Med 10:218. 2012
  2. pmc BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, Crump Institute for Molecular Imaging, UCLA Biomedical Physics Interdepartmental Graduate Program, Los Angeles, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer Res 72:3928-37. 2012
  3. pmc Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 107:14286-91. 2010
  4. ncbi request reprint Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Ther 15:971-80. 2007
  5. ncbi request reprint Immunosensitization with a Bcl-2 small molecule inhibitor
    Jonathan Begley
    Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Cancer Immunol Immunother 58:699-708. 2009
  6. ncbi request reprint Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression
    Takahiro Kimura
    Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    Mol Ther 15:1390-9. 2007
  7. pmc Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
    Erika von Euw
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
    Mol Cancer 11:22. 2012
  8. pmc The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy
    Paul C Tumeh
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles UCLA, Los Angeles, California, USA
    J Immunother 33:759-68. 2010
  9. pmc Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
    Hubing Shi
    Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095 1750, USA
    Cancer Discov 2:414-24. 2012
  10. pmc The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 16:6040-8. 2010

Collaborators

Detail Information

Publications33

  1. pmc A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
    Adrian Bot
    Kite Pharma Inc, Los Angeles, CA, USA
    J Transl Med 10:218. 2012
    ..This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy...
  2. pmc BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, Crump Institute for Molecular Imaging, UCLA Biomedical Physics Interdepartmental Graduate Program, Los Angeles, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer Res 72:3928-37. 2012
    ..Taken together, our findings, derived from 2 independent models combining BRAF-targeted therapy with immunotherapy, support the testing of this therapeutic combination in patients with BRAFV600 mutant metastatic melanoma...
  3. pmc Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 107:14286-91. 2010
    ..This approach of TCR engineering and molecular imaging reporter gene labeling is directly translatable to humans and provides useful information on how to clinically develop this mode of therapy...
  4. ncbi request reprint Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Ther 15:971-80. 2007
    ..Thus, DC precursors can be genetically engineered after a single ex vivo manipulation, resulting in DC vaccines with improved activity...
  5. ncbi request reprint Immunosensitization with a Bcl-2 small molecule inhibitor
    Jonathan Begley
    Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Cancer Immunol Immunother 58:699-708. 2009
    ....
  6. ncbi request reprint Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression
    Takahiro Kimura
    Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    Mol Ther 15:1390-9. 2007
    ..These studies reveal that APC transduction by LVs could lead to immune reactivity (LV-CMV) or persistence of transgene expression (LV-MHCII), providing a relevant paradigm for vaccination and gene replacement approaches...
  7. pmc Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
    Erika von Euw
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
    Mol Cancer 11:22. 2012
    ..TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2...
  8. pmc The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy
    Paul C Tumeh
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles UCLA, Los Angeles, California, USA
    J Immunother 33:759-68. 2010
    ....
  9. pmc Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
    Hubing Shi
    Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095 1750, USA
    Cancer Discov 2:414-24. 2012
    ..Thus, activating MEK1 exon 3 mutations identified herein and concurrent with V600E/KBRAF do not cause BRAFi resistance in melanoma...
  10. pmc The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 16:6040-8. 2010
    ..Combining PLX4032 with immunotherapy may allow expanding the durability of responses. The effects of PLX4032 on immune cells were studied to explore the feasibility of future combinatorial approaches with immunotherapy for melanoma...
  11. pmc Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
    Hubing Shi
    Division of Dermatology, Department of Medicine, University of California, Los Angeles, 52 121 CHS, 10833 Le Conte Avenue, California 90095 1750, USA
    Nat Commun 3:724. 2012
    ..Thus, alternative clinical strategies may potentially overcome distinct modes of extracellular signal-regulated kinase reactivation underlying acquired B-RAF inhibitor resistance in melanoma...
  12. pmc Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma
    Begona Comin-Anduix
    Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 5:e12711. 2010
    ....
  13. pmc Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    Ramin Nazarian
    Division of Dermatology Department of Medicine, UCLA s Jonsson Comprehensive Cancer Center, 52 121 CHS, Los Angeles, California 90095 1750, USA
    Nature 468:973-7. 2010
    ....
  14. pmc CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans
    Rong Rong Huang
    Division of Hematology Oncology, 11 934 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 17:4101-9. 2011
    ..A key question is defining whether the intratumoral infiltration (ITI) is a differentiating factor between patients with and without tumor responses...
  15. pmc Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
    Hubing Shi
    1Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine 4Jonsson Comprehensive Cancer Center 5Department of Molecular and Medical Pharmacology 6David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California Departments of 7Medicine, 8Cancer Biology, and 9Surgery, 10Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 11Melanoma Institute of Australia, Westmead Millennium Institute, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia and 12Ludwig Institute for Cancer Research, Brussels Branch, Belgium
    Cancer Discov 4:80-93. 2014
    ..Thus, melanoma genomic heterogeneity contributes significantly to BRAF inhibitor treatment failure, implying upfront, cotargeting of two core pathways as an essential strategy for durable responses. ..
  16. pmc CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
    Erika von Euw
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California, USA
    J Transl Med 7:35. 2009
    ..We studied the levels of this T cell subset in peripheral blood of patients treated with the anti-CTLA4 antibody tremelimumab since its major dose limiting toxicities are inflammatory and autoimmune in nature...
  17. pmc Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy
    Stephen Mok
    Authors Affiliations Department of Molecular and Medical Pharmacology Jonsson Comprehensive Cancer Center Surgery, Division of Surgical Oncology Institute for Molecular Medicine Departments of Urology and Pediatrics Crump Institute for Molecular Imaging Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles Plexxikon Inc, Berkeley, California and Roswell Park Cancer Institute, Buffalo, New York
    Cancer Res 74:153-61. 2014
    ..In conclusion, CSF-1R blockade with PLX3397 improved the efficacy of ACT immunotherapy by inhibiting the intratumoral accumulation of immunosuppressive macrophages...
  18. pmc Natural killer T cells in advanced melanoma patients treated with tremelimumab
    F Javier Ibarrondo
    Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America UCLA AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 8:e76829. 2013
    ..These results indicate that iNKT cells play a critical role in regulating effective antitumor T cell activity. ..
  19. pmc T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy
    Jon G Quatromoni
    Department of Surgery, University of California, Los Angeles, CA 90095, USA
    J Transl Med 10:127. 2012
    ..These results support efforts to incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer...
  20. ncbi request reprint The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles UCLA, CA 90095, USA
    J Immunol 176:157-64. 2006
    ..Nevertheless, immunotherapeutic targeting of malignant CNS tumors may be enhanced by the administration of the innate immune response modifier imiquimod...
  21. pmc Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    Jonas N Søndergaard
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 8:39. 2010
    ..In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity...
  22. ncbi request reprint Immune rejection in a humanized model of murine prostate cancer
    Dorthe Schaue
    Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1714, USA
    Anticancer Res 30:409-14. 2010
    ..Background/Aim: We attempted to develop a humanized mouse model for prostate cancer to study immune recognition and responses to human prostate-tumor antigens in mice...
  23. pmc A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition
    Hubing Shi
    1The Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine, 4Jonsson Comprehensive Cancer Center, 5Department of Molecular and Medical Pharmacology, 6David Geffen School of Medicine, University of California, Los Angeles, California 7Melanoma Institute of Australia, 8Royal Prince Alfred Hospital, 9Westmead Millennium Institute, and 10Westmead Hospital, University of Sydney, New South Wales, Australia
    Cancer Discov 4:69-79. 2014
    ..In addition, mitogen-activated protein kinase pathway inhibition enhanced clonogenic growth dependency on PI3K or AKT. Thus, adaptive or genetic upregulation of AKT critically participates in melanoma survival during BRAFi therapy. ..
  24. ncbi request reprint Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models
    Frédéric D Birkhäuser
    Institute of Urologic Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA
    J Immunother 36:102-11. 2013
    ....
  25. pmc Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway
    Veerauo V Konkankit
    Graduate Program in Physiological Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, 90095, USA
    J Transl Med 9:192. 2011
    ..However, the absence of well-characterized, highly immunogenic tumor-rejection antigens (TRA) in gliomas has limited the implementation of targeted immune-based therapies...
  26. doi request reprint siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide
    Jonathan E Zuckerman
    Division of Hematology Oncology, Department of Medicine, UCLA Medical Center, Los Angeles, California 90095 1782, USA
    J Invest Dermatol 131:453-60. 2011
    ..In conclusion, siRNA-mediated RRM2 knockdown significantly inhibits proliferation of melanoma cell lines with different oncogenic mutations with synergistic enhancement in combination with temozolomide...
  27. pmc CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
    Lidia Robert
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, Departments of Molecular and Medical Pharmacology, Medicine Statistics core, and Pathology and Laboratory Medicine, Division of Surgical Oncology, Department of Surgery, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California Fred Hutchinson Cancer Research Center Adaptive Biotechnologies, Seattle, Washington and Instituto de Salud Carlos III, Madrid, Spain
    Clin Cancer Res 20:2424-32. 2014
    ..To evaluate the immunomodulatory effects of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blockade with tremelimumab in peripheral blood mononuclear cells (PBMC)...
  28. pmc Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy
    Chao Ma
    NanoSystems Biology Cancer Center, Division of Physics, California Institute of Technology, Pasadena, CA 91125, USA
    Cancer Discov 3:418-29. 2013
    ..This study highlights the need to develop approaches to maintaining antitumor T-cell functionality with the aim of increasing the long-term efficacy of TCR-engineered ACT immunotherapy...
  29. doi request reprint Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction
    Ali R Jazirehi
    Department of Surgery, Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Cancer Res 71:1406-17. 2011
    ..Though unresponsive to CTL, our results argue that resistant cells can be resensitized to immunotherapy with coadministration of targeted inhibitors to antiapoptotic survival pathways...
  30. ncbi request reprint Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery
    Richard C Koya
    Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    J Immunother 26:451-60. 2003
    ....
  31. ncbi request reprint The use of lentiviral vectors in gene therapy of leukemia: combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors
    Renata Stripecke
    Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Blood Cells Mol Dis 31:28-37. 2003
    ..Therefore, lentiviral vectors offer a simple, versatile, and reliable approach for engineering leukemic cells for use as cell vaccines...
  32. ncbi request reprint Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro
    Richard C Koya
    Department of Medicine, UCLA Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Hum Gene Ther 15:733-48. 2004
    ..This article demonstrates the proof-of-concept to genetically convert monocytes to DC-type antigen-presenting cells with lentiviral vectors...
  33. pmc Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells
    Dimitrios N Vatakis
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles CA 90095, USA
    Proc Natl Acad Sci U S A 108:E1408-16. 2011
    ..These studies present a potential therapeutic approach and an important tool to understand better and to optimize the human immune response to melanoma and, potentially, to other types of cancer...